Is retatrutide FDA-approved, and what does the research show?

What is retatrutide?

Retatrutide is an investigational peptide drug; its trials were funded by Eli Lilly ¹. It is a triple-receptor agonist: one molecule that switches on three hormone receptors, GIP, GLP-1 and glucagon ³. GIP and GLP-1 are incretin hormones, gut hormones that prompt the pancreas to release insulin after a meal ⁶. Semaglutide acts on the GLP-1 receptor and tirzepatide on GLP-1 and GIP; retatrutide adds glucagon ⁶, ¹.

Is retatrutide FDA-approved?

Retatrutide is not FDA-approved: Drugs@FDA lists no approved retatrutide product as of November 9, 2026 ². It is an investigational drug studied in phase 3 trials ³, ⁴. The Lancet trial paper describes it as "currently under investigation" for obesity, type 2 diabetes and other conditions ⁴. Two phase 3 trials, in the October and November 2026 issues of The Lancet and the New England Journal of Medicine, tested it against placebo ³, ⁴.

See the FDA status of every peptide, updated weekly.

How does retatrutide work?

Retatrutide acts on three receptors: GIP, GLP-1 and glucagon ³, ¹. GLP-1 and GIP are incretin hormones that stimulate insulin secretion after a glucose load ⁶. Drugs acting on the GLP-1 receptor also delay stomach emptying and reduce glucagon release when blood sugar is high ⁶. The glucagon arm's contribution is proposed ⁵. The liver substudy's authors write that its glucagon activity "may reduce liver fat by stimulating hepatic fatty acid oxidation and reducing hepatic lipogenesis", drawing on preclinical work ⁵.

What does the research show?

Studied in people: a randomized, double-blind, placebo-controlled phase 2 trial, 338 adults with obesity or overweight, weight change at 48 weeks ¹. Mean weight fell by 8.7% to 24.2% across the retatrutide groups, against 2.1% with placebo ¹.

Studied in people: TRIUMPH-1, a randomized, double-blind phase 3 trial, 2,339 adults with obesity or overweight and without diabetes, weight change at 80 weeks ³. Mean weight fell by 17.6% to 25.0% across the three retatrutide groups, against 3.9% with placebo ³.

Studied in people: TRIUMPH-2, a randomized, double-blind, placebo-controlled phase 3 trial, 1,152 adults with obesity or overweight and type 2 diabetes, weight change at 80 weeks ⁴. Mean weight fell by 11.9% to 18.8%, against 5.1% with placebo, and the authors report improved blood sugar control ⁴.

Studied in people: a randomized, placebo-controlled phase 2a substudy, liver fat at 24 weeks ⁵. Its participants were 98 of the 338 above, with metabolic dysfunction-associated steatotic liver disease and at least 10 percent liver fat ⁵. Liver fat fell by 42.9% to 82.4% across the retatrutide groups, while placebo rose by 0.3% ⁵.

These trials ran for 80 weeks at most ³, ¹, ⁵, ⁴.

What are the side effects?

In the weight trials, the most common adverse events were gastrointestinal ³, ¹, ⁴. In the phase 2 trial of 338 adults with obesity or overweight, these events were dose-related and mostly mild to moderate ¹. Heart rate rose with dose, peaked at 24 weeks, then declined ¹. In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, diarrhea affected 27% to 34% of retatrutide participants against 13% on placebo ⁴. Nausea affected 14% to 28% against 8% ⁴. Discontinuation for adverse events or death ran from 4% to 12% across retatrutide groups, against 5% with placebo ⁴. Seven participants died, six on retatrutide; the investigators judged every death unrelated to the drug ⁴. FDA has approved no retatrutide product, so no FDA label exists to quote on safety ².

In sport

Retatrutide is not named on WADA's 2026 Prohibited List ⁷. WADA is the World Anti-Doping Agency. Neither its peptide-hormone section S2 nor its metabolic-modulator section S4 names it ⁷. Section S0 of the list also prohibits at all times "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use" ⁷. This page draws no conclusion on whether S0 covers retatrutide.

What JumpstartMD offers

JumpstartMD does not prescribe retatrutide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.